ValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors

BETHESDA, Md.--(BUSINESS WIRE)--ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory indications, today announced the appointment of Peter Greenleaf to its board of directors. Mr. Greenleaf, a seasoned industry executive with nearly 30 years of experience leading successful life sciences companies, is currently the president, chief executive officer and member of the Board of Aurinia Pharmaceuticals, Inc., a fully integr